NCT07051109 Dual-chamber Patient-controlled Analgesia for Postoperative Recovery
| NCT ID | NCT07051109 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Bundang Hospital |
| Condition | Morbid Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 92 participants |
| Start Date | 2022-10-11 |
| Primary Completion | 2025-08-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 92 participants in total. It began in 2022-10-11 with a primary completion date of 2025-08-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Postoperative nausea and vomiting (PONV) are the most common complications that can occur after general anesthesia. Postoperative use of opioids and morbid obesity have been reported as risk factors of PONV. In this study, the investigators aimed to compare the degree of postoperative side effects and pain control when an intravenous patient-controlled analgesia combining fentanyl and ketorolac via a dual-chamber device was provided to participants undergoing laparoscopic sleeve gastrectomy.
Eligibility Criteria
Inclusion Criteria: * Adult females aged 19 to 65 years * American Society of Anesthesiologists physical status (ASA class) 1 to 3 * Patients scheduled for laparoscopic sleeve gastrectomy under general anesthesia * Patients requesting the use of IV-PCA after surgery Exclusion Criteria: * Patients with hypersensitivity to the drugs used in this study (Ketorolac, Fentanyl) * Patients with alcohol or drug dependence, long-term use of opioids or analgesics * Patients with liver disease or renal failure * Patients with peptic ulcer, patients with gastrointestinal bleeding predisposition * Patients with suspected cerebrovascular hemorrhage, organic disorders of the head related to increased intracranial pressure * Patients with bronchial asthma or bronchospasm symptoms * Patients with severe respiratory depression * Nasal polyps, angioedema * Patients with or history of convulsive disease * Patients for whom the use of neuromuscular blocking agents is contraindicated
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07051109 clinical trial?
This trial is open to female participants only, aged 19 Years or older, up to 65 Years, studying Morbid Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07051109 currently recruiting?
Yes, NCT07051109 is actively recruiting participants. Contact the research team at pis121@hanmail.net for enrollment information.
Where is the NCT07051109 trial being conducted?
This trial is being conducted at Seongnam-si, South Korea.
Who is sponsoring the NCT07051109 clinical trial?
NCT07051109 is sponsored by Seoul National University Bundang Hospital. The trial plans to enroll 92 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.